|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
SCIDIR_ocn988219732 |
| 003 |
OCoLC |
| 005 |
20231120112229.0 |
| 006 |
m o d |
| 007 |
cr mn||||||||| |
| 008 |
170426t20172017ne ob 000 0 eng d |
| 040 |
|
|
|a NLE
|b eng
|e rda
|e pn
|c NLE
|d OCLCO
|d YDX
|d N$T
|d EBLCP
|d OPELS
|d IDEBK
|d OCLCF
|d MERER
|d OCLCQ
|d GZM
|d OCLCQ
|d OTZ
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|d D6H
|d OCLCO
|d OCLCQ
|d U3W
|d OCLCQ
|d OCLCO
|d AU@
|d OCLCO
|d WYU
|d OCLCO
|d OCLCQ
|d OCLCA
|d OCLCQ
|d UKMGB
|d OCLCQ
|d OCLCO
|d OSU
|d CASUM
|d LVT
|d COM
|d OCLCO
|d OCLCQ
|d SFB
|d OCLCO
|
| 015 |
|
|
|a GBB778016
|2 bnb
|
| 016 |
7 |
|
|a 018333043
|2 Uk
|
| 019 |
|
|
|a 986802925
|a 987055475
|a 987316342
|a 993949038
|a 1010959134
|a 1229748264
|a 1311348941
|
| 020 |
|
|
|a 9780128094457
|q (ePub ebook)
|
| 020 |
|
|
|a 0128094451
|q (ePub ebook)
|
| 020 |
|
|
|z 9780128094006
|q (hbk.)
|
| 020 |
|
|
|z 0128094001
|q (hbk.)
|
| 035 |
|
|
|a (OCoLC)988219732
|z (OCoLC)986802925
|z (OCoLC)987055475
|z (OCoLC)987316342
|z (OCoLC)993949038
|z (OCoLC)1010959134
|z (OCoLC)1229748264
|z (OCoLC)1311348941
|
| 050 |
|
4 |
|a RC271.P76
|b T75 2017eb
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.994061
|2 23
|
| 100 |
1 |
|
|a Tridente, G.,
|e author.
|
| 245 |
1 |
0 |
|a Adverse events and oncotargeted kinase inhibitors /
|c Giuseppe Tridente.
|
| 264 |
|
1 |
|a Amsterdam :
|b Academic Press,
|c [2017]
|
| 264 |
|
4 |
|c �2017
|
| 300 |
|
|
|a 1 online resource (xix, 715 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Introduction -- Kinases -- Kinase inhibitors -- Adverse events -- Imantinib -- Gefitinib -- Erlotinib -- Sorafenib -- Sunitinib -- Dasatinib -- Lapatinib -- Nilotinib -- Pazopanib -- Vandetanib -- Vemurafenib -- Crizotinib -- Ruxolitinib -- Axitinib -- Bosutinib -- Regorafenib -- Cabozantinib -- Ponatinib -- Dabrafenib -- Trametinib -- Afatinib -- Idelaisib -- Ibrutinib -- Overview -- Conclusion and perspectives.
|
| 588 |
|
|
|a Description based on print version record
|
| 650 |
|
0 |
|a Protein-tyrosine kinase
|x Inhibitors
|x Therapeutic use.
|
| 650 |
|
0 |
|a Protein-tyrosine kinase
|x Inhibitors.
|
| 650 |
|
2 |
|a Protein-Tyrosine Kinases
|x antagonists & inhibitors
|0 (DNLM)D011505Q000037
|
| 650 |
|
6 |
|a Prot�eine-tyrosine kinase
|x Inhibiteurs.
|0 (CaQQLa)201-0372706
|
| 650 |
|
6 |
|a Prot�eine-tyrosine kinase
|0 (CaQQLa)201-0372706
|x Inhibiteurs
|0 (CaQQLa)201-0372706
|x Emploi en th�erapeutique.
|0 (CaQQLa)201-0373975
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Protein-tyrosine kinase
|x Inhibitors
|2 fast
|0 (OCoLC)fst01079707
|
| 655 |
|
0 |
|a Electronic books.
|
| 655 |
|
4 |
|a Internet Resources.
|
| 776 |
0 |
8 |
|i Print version:
|a Tridente, G.
|t Adverse events and oncotargeted kinase inhibitors.
|d London : Elsevier/Academic Press, [2017]
|z 9780128094006
|w (DLC) 2017302047
|w (OCoLC)959880103
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128094006
|z Texto completo
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128094006
|z Texto completo
|
